For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Recursion Pharmaceuticals Inc’s stock clocked out at $5.06, up 0.60% from its previous closing price of $5.03. In other words, the price has increased by $0.60 from its previous closing price. On the day, 25.62 million shares were traded. RXRX stock price reached its highest trading level at $5.27 during the session, while it also had its lowest trading level at $5.01.
Ratios:
To gain a deeper understanding of RXRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 4.11. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 27 ’25 when Gibson Christopher sold 138,574 shares for $6.04 per share. The transaction valued at 836,987 led to the insider holds 1,117,450 shares of the business.
Gibson Christopher bought 138,574 shares of RXRX for $836,987 on Mar 27 ’25. On Mar 05 ’25, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 20,000 shares for $6.58 each. As a result, the insider received 131,600 and left with 1,256,024 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2056864768 and an Enterprise Value of 1651454464. For the stock, the TTM Price-to-Sale (P/S) ratio is 34.40 while its Price-to-Book (P/B) ratio in mrq is 2.20. Its current Enterprise Value per Revenue stands at 27.621 whereas that against EBITDA is -3.142.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.89, which has changed by -0.2932961 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is 3.03%, while the 200-Day Moving Average is calculated to be -20.12%.
Shares Statistics:
It appears that RXRX traded 24.93M shares on average per day over the past three months and 27498880 shares per day over the past ten days. A total of 399.15M shares are outstanding, with a floating share count of 310.65M. Insiders hold about 23.58% of the company’s shares, while institutions hold 60.54% stake in the company. Shares short for RXRX as of 1749772800 were 120075634 with a Short Ratio of 4.82, compared to 1747267200 on 104219046. Therefore, it implies a Short% of Shares Outstanding of 120075634 and a Short% of Float of 31.870001999999996.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 6.0 analysts. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.27 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.23 and -$1.64 for the fiscal current year, implying an average EPS of -$1.46. EPS for the following year is -$1.14, with 9.0 analysts recommending between -$0.81 and -$1.46.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $16.23M. It ranges from a high estimate of $27.7M to a low estimate of $5M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $14.42MFor the next quarter, 6 analysts are estimating revenue of $20.03M. There is a high estimate of $28.9M for the next quarter, whereas the lowest estimate is $5M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $115.5M, while the lowest revenue estimate was $44.85M, resulting in an average revenue estimate of $70.98M. In the same quarter a year ago, actual revenue was $58.84MBased on 9 analysts’ estimates, the company’s revenue will be $106.78M in the next fiscal year. The high estimate is $208.4M and the low estimate is $45M.
